New Zealand Markets closed

Qiagen N.V. (QGEN)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
46.15+0.32 (+0.70%)
At close: 04:00PM EDT
46.15 +0.02 (+0.03%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close45.83
Bid35.04 x 800
Ask53.00 x 900
Day's range45.58 - 46.15
52-week range40.38 - 51.18
Avg. volume658,347
Market cap10.508B
Beta (5Y monthly)0.38
PE ratio (TTM)30.16
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results

    VENLO, The Netherlands, March 13, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.

  • Business Wire

    QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug

    VENLO, the Netherlands, March 09, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia (AML).

  • Business Wire

    QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing

    VENLO, Netherlands, March 01, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the new QIAseq Platform Partnership program and the first partnership with medical data-analysis provider SOPHiA GENETICSTM (Nasdaq: SOPH) that will bring together its QIAseq reagent technology for next-generation sequencing (NGS) with the SOPHiA DDMTM digital analytics platform.